CN115337223A - Anti-wrinkle composition and application thereof - Google Patents
Anti-wrinkle composition and application thereof Download PDFInfo
- Publication number
- CN115337223A CN115337223A CN202210865461.XA CN202210865461A CN115337223A CN 115337223 A CN115337223 A CN 115337223A CN 202210865461 A CN202210865461 A CN 202210865461A CN 115337223 A CN115337223 A CN 115337223A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- wrinkle
- humectant
- preservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 47
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 18
- 239000003906 humectant Substances 0.000 claims abstract description 18
- 239000003755 preservative agent Substances 0.000 claims abstract description 18
- 230000002335 preservative effect Effects 0.000 claims abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 59
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 22
- 235000011187 glycerol Nutrition 0.000 claims description 22
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 18
- 229960005323 phenoxyethanol Drugs 0.000 claims description 18
- 239000008213 purified water Substances 0.000 claims description 14
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 13
- 239000011570 nicotinamide Substances 0.000 claims description 13
- 229960003966 nicotinamide Drugs 0.000 claims description 13
- 235000005152 nicotinamide Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 6
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- UITSPQLTFPTHJZ-UHFFFAOYSA-N 2-[[3,4,5-tris(2-hydroxyethoxy)-6-methoxyoxan-2-yl]methoxy]ethanol Chemical compound COC1OC(COCCO)C(OCCO)C(OCCO)C1OCCO UITSPQLTFPTHJZ-UHFFFAOYSA-N 0.000 claims description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229960004365 benzoic acid Drugs 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- -1 glyceryl glucoside Chemical class 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229940100485 methyl gluceth-10 Drugs 0.000 claims description 3
- 229940031722 methyl gluceth-20 Drugs 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 229960003885 sodium benzoate Drugs 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 229940105990 diglycerin Drugs 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000010931 gold Substances 0.000 abstract description 4
- 229910052737 gold Inorganic materials 0.000 abstract description 4
- 230000035515 penetration Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 27
- 206010040954 Skin wrinkling Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 230000037303 wrinkles Effects 0.000 description 21
- 108030001720 Bontoxilysin Proteins 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 229940053031 botulinum toxin Drugs 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 102000034426 Rabphilin-3A Human genes 0.000 description 3
- 108010002368 Rabphilin-3A Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Abstract
The invention belongs to the field of bioengineering, and particularly relates to an anti-wrinkle composition and application thereof. The invention provides an anti-wrinkle composition, which comprises a polypeptide nano hybrid, nicotinamide, a humectant, a preservative and water. The invention also provides application of the anti-wrinkle composition in preparing an anti-wrinkle product. The anti-wrinkle composition provided by the invention is not easy to degrade, and can be absorbed by skin more easily through nano-gold penetration film, so that a better anti-wrinkle effect is achieved.
Description
Technical Field
The invention belongs to the field of bioengineering, and particularly relates to an anti-wrinkle composition and application thereof.
Background
Wrinkles are the signs of aging of the human body gradually due to the gravity effect of the earth and some changes of the human body in the natural aging process. The method mainly comprises the following steps: 1. dynamic wrinkles, such as crow's feet, forehead lines and CHUAN-shaped lines, which are caused by dynamic contraction of facial muscles; 2. volume-related wrinkles, which are likely to appear as the skin and subcutaneous tissue become less organized with age up to 45 years old; 3. gravity wrinkles, i.e. wrinkles caused by bony atrophy, by the age of sixty-seventy, the bones are involved in atrophy, i.e. the structure of the entire support body is reduced, and a third layer of wrinkles is formed. Different treatments should be used to solve the problem of wrinkles at different ages. The main anti-wrinkle effects in the market are botulinum toxin and the hexapeptide appearing in recent years, and the botulinum toxin and the hexapeptide have disadvantages.
Botulinum toxin, also known as botulinum toxin, is a neurotoxin protein produced by botulinum bacteria during the process of propagation. Botulinum toxin is a 150kD polypeptide consisting of a 100kD heavy (H) chain linked to a 50kD light (L) chain by a disulfide bond. Based on their toxicity and antigenicity, they are classified into A, B and C a 、C b D, E, F and G8 types. Botulinum toxin is one of the most toxic natural substances and one of the most toxic proteins in the world, and 1mg of purified and crystallized botulinum toxin can kill 2 hundred million mice, and the semi-lethal dose to humans is 40IU/Kg. But has stable properties, is easy to produce,And (4) purifying and refining. Therefore, it was first used in experimental research and clinical practice. Botulinum toxin can eliminate wrinkles or avoid the formation of wrinkles for a period of time by paralyzing relaxed subcutaneous nerves, thereby achieving a cosmetic effect. Because botulinum toxin is expensive and requires constant injections to maintain its effectiveness. Botulinum toxin injection surgery carries a certain risk and must be performed by a professional dermatologist or facial cosmetic doctor to be safe and reliable, which is not the case in beauty salons in general.
At present, the peptide which can be compared with botulinum toxin on the market is hexapeptide, the common name of the hexapeptide (botulinum toxin) is acetyl hexapeptide-8 (ayorelin) which is a small molecule formed by combining six amino acids and is a famous wrinkle-removing active ingredient, and the mechanism of the peptide is to inhibit the release of neurotransmitter acetylcholine (acetylcholine), so that the contraction of muscles can be reduced, and the generation of dynamic lines and expression lines is reduced, mainly aiming at the dynamic lines. The hexapeptide is not botulinum toxin and has no toxicity, so the hexapeptide is quite safe to use, is only externally used and does not need to be injected, and is widely used in high-grade maintenance products. However, the hexapeptide is easy to degrade and not easy to be absorbed by skin, and the effect is greatly reduced. Therefore, a need exists for a botulinum toxin polypeptide product with strong anti-wrinkle efficacy which is not easily degraded and easily absorbed by the skin.
Disclosure of Invention
In order to solve the defects of the prior art, the invention provides an anti-wrinkle composition and application of the anti-wrinkle composition in preparing an anti-wrinkle product. The anti-wrinkle composition provided by the invention has good effect of eliminating or reducing wrinkles.
The purpose of the invention is realized by the following technical scheme:
in a first aspect, the present invention provides an anti-wrinkle composition comprising a polypeptide nanohybrid, niacinamide, a humectant, a preservative, and water.
In a preferred embodiment, the structure of the polypeptide nano-hybrid is [ Au-S-S-pentadecapeptide ] n.
In a more preferred embodiment, the amino acid sequence of the pentadecapeptide is sefmrneelemmqrra.
In a preferred embodiment, the preservative is one or more of methylparaben, propylparaben, phenoxyethanol, glyceryl caprylate, ethylhexyl glycerin, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, caprylhydroxamic acid, and glyceryl caprylate.
In a more preferred embodiment, the preservative is phenoxyethanol.
In a preferred embodiment, the humectant is one or more of glycerin, diglycerin, propylene glycol, butylene glycol, methyl gluceth-10, methyl gluceth-20, glyceryl polyether-7, glyceryl polyether-26, glyceryl glucoside, sucrose, rhamnose, mannose, raffinose, betaine, erythritol, and xylitol.
In a more preferred embodiment, the humectant is glycerin, butylene glycol, or a mixture thereof.
In a preferred embodiment, the composition comprises, by weight, 0.5 to 20 parts of the polypeptide nano-hybrid, 0.1 to 1 part of nicotinamide, 1 to 8 parts of a humectant, 0 to 0.4 part of a preservative, and water.
In preferred embodiments, the weight fraction of the polypeptide nano-hybrid may be 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 parts.
In a preferred embodiment, the weight fraction of nicotinamide may be 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part or 1 part.
In a preferred embodiment, the humectant may be present in a weight fraction of 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, or 8 parts.
In preferred embodiments, the preservative may be present in a weight fraction of 0.1, 0.2, 0.3 or 0.4 parts.
In a preferred embodiment, the composition comprises 10 parts by weight of the polypeptide nano-hybrid, 1 part of nicotinamide, 6 parts of the humectant, 0.4 part of the preservative and water.
In a preferred embodiment, the composition comprises 10 parts polypeptide nano-hybrid, 1 part niacinamide, 4 parts glycerol, 2 parts butanediol, 0.4 part phenoxyethanol, and water, by weight parts.
In a preferred embodiment, the structure of the polypeptide nano-hybrid is [ Au-S-pentadecapeptide ] n, and the amino acid sequence of the pentadecapeptide is sefmrneelemmqrra.
In a preferred embodiment, the preservative is one or more of methylparaben, propylparaben, phenoxyethanol, glyceryl caprylate, ethylhexyl glycerin, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, caprylhydroxamic acid, and glyceryl caprylate.
In a more preferred embodiment, the preservative is phenoxyethanol.
In a preferred embodiment, the humectant is one or more of glycerol, diglycerol, propylene glycol, butylene glycol, methyl gluceth-10, methyl gluceth-20, glyceryl polyether-7, glyceryl polyether-26, glyceryl glucoside, sucrose, rhamnose, mannose, raffinose, betaine, erythritol, and xylitol.
In a more preferred embodiment, the humectant is glycerin, butylene glycol, or a mixture thereof.
In a second aspect, the method for preparing the anti-wrinkle composition according to the present invention comprises the steps of:
s1, respectively weighing the following raw materials: humectant, nicotinamide, polypeptide nano-composition, preservative and purified water.
S2, adding the purified water and the humectant weighed in the step S1 into a container, mixing, heating to 80-85 ℃, and uniformly stirring to obtain a phase A;
s3, cooling to 40-45 ℃, adding the nicotinamide, the polypeptide nano composition and the preservative which are weighed in the step S1 into the phase A obtained in the step S2, and stirring for 20-30min to obtain the anti-wrinkle composition.
In a third aspect, there is provided use of an anti-wrinkle composition according to the present invention in the manufacture of an anti-wrinkle product. The anti-wrinkle product includes but is not limited to freeze-dried powder, facial mask, smoothing toner, essence, emulsion, cream, facial cleanser and shower gel.
In a preferred embodiment, the polypeptide nano-hybrid comprises nanogold and a pentadecapeptide, wherein the nanogold is bonded to the polypeptide through an Au-S bond, and the amino acid sequence of the pentadecapeptide is SEFMRNELEEMQRRA.
In a preferred embodiment, the method for preparing the polypeptide nano-hybrid comprises the following steps:
s1, obtaining an amino acid sequence of pentadecapeptide through computer-aided simulation and structural design;
s2, synthesizing a cysteine-modified Rabphilin-3A antagonist by utilizing an Fmoc solid-phase synthesis method to obtain pentadecapeptide-SH;
s3, dissolving dried pentadecapeptide-SH in NH 2 Adding hydroxyethyl piperazine ethyl sulfonic acid and HAuCl into a mixed solution of-PEG-SH, absolute ethyl alcohol and pure water until pentadecapeptide-SH is completely dissolved 4 Vortex and stir to obtain Au-peptide precursor;
s4, adding hydroxyethyl piperazine ethyl sulfonic acid and HAuCl 4 Mixing with pure water, and stirring in a vortex manner to obtain a nano gold solution;
s5, adding the Au-peptide precursor into the nano-gold solution to obtain the polypeptide nano hybrid.
In the present invention, the nicotinamide is purchased from Beijing Xinnuojiu Hengkoku GmbH, with a lot number of 201001. The polypeptide nano hybrid is purchased from Shanxi future polypeptide Biotechnology GmbH with the batch number of 201210.
As used herein, the term "peptide" or "polypeptide" refers to natural and synthetic peptides, which may comprise only natural amino acids, only unnatural amino acids, or a combination of natural and unnatural amino acids. As used herein, the term "polypeptide" includes oligopeptides, peptides, polypeptides and derivatives thereof, peptide analogs and derivatives thereof, and pharmaceutically acceptable salts of these compounds. "peptide analogs" refers to synthetically modified amino acids or peptides. As used herein, the term "peptide" also includes complexes with other species such as metal ions (e.g., copper, zinc, manganese, magnesium, etc.).
As used herein, the term "amino acid" includes and encompasses all naturally occurring and unnatural amino acids, if optically active, in either the D-or L-configuration. As used herein, the term "pentadecapeptide" is a compound that includes within its structure an uninterrupted sequence of fifteen amino acids. These are represented herein from left (N-terminal) to right (C-terminal) using the traditional three letter convention. In this nomenclature, S is serine, E is glutamic acid, F is phenylalanine, M is methionine, R is arginine, N is asparagine, L is leucine, Q is glutamine, and A is alanine.
Compared with the prior art, the invention has the beneficial effects that:
the polypeptide nano hybrid provided by the invention is a new polypeptide sequence obtained by intercepting key amino acids according to effective binding amino acid sites between SNAP25 and Rabphilin-3A, and has stronger affinity with Rabphilin-3A and 5-6 orders of magnitude higher affinity.
Most of short peptides used in the existing anti-wrinkle composition are below decapeptide, and the stability, affinity and skin barrier permeation of the short peptides are not ideal. Botulinum toxin type a is limited by its dose and reversible effects, and chronic injections may cause chronic and serious adverse reactions, such as dyspnea, muscle weakness, granulomatous granulomas, headache, flu-like symptoms, allergic reactions, and the like. The polypeptide nano hybrid provided by the invention is a pentadecapeptide imitating A-type botulinum toxin, has good stability, permeability and affinity, shows good biocompatibility, can better penetrate cell membranes and resist protease hydrolysis, so that acetylcholine conduction between nerve and muscle can be better prevented, muscle paralysis can be caused, muscle can be relaxed, and dynamic wrinkles can be reduced, thereby eliminating fine wrinkles.
The anti-wrinkle hybrid provided by the invention can well protect the activity of the polypeptide nano hybrid, is not easy to degrade, and is easier to be absorbed by skin through nano gold penetration film, so that a better anti-wrinkle effect is achieved.
Drawings
FIG. 1 is a graph showing the results of the permeation rate of a drug through the skin;
FIG. 2 is a graph of the results of experiment 3, before application and 28 days after application, for the volunteer of example 1, tested by a VISIA instrument;
FIG. 3 is a graph of the results of the test conducted by the VISIA apparatus in experiment 3 before and 28 days after the application to the volunteers of example 2;
FIG. 4 is a graph of the results of the test conducted by the VISIA meter in experiment 3 before and 28 days after the application to the volunteers of example 3;
fig. 5 is a graph showing the results of experiment 3 before application and 28 days after application to the volunteers of example 4, which were tested by a VISIA instrument.
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are illustrative of the invention and are not to be construed as limiting the invention.
Example 1
This example provides an anti-wrinkle composition, which includes, in parts by weight, 0.5 part of a polypeptide nano-hybrid, 0.1 part of nicotinamide, 0.5 part of glycerol, 0.5 part of butylene glycol, 0.1 part of phenoxyethanol, and an appropriate amount of purified water.
Example 2
The embodiment provides an anti-wrinkle composition, which comprises, by weight, 20 parts of a polypeptide nano-hybrid, 1 part of nicotinamide, 4 parts of glycerol, 2 parts of butanediol, 0.4 part of phenoxyethanol, and a proper amount of purified water.
Example 3
The embodiment provides an anti-wrinkle composition, which comprises, by weight, 10 parts of a polypeptide nano-hybrid, 1 part of nicotinamide, 4 parts of glycerol, 2 parts of butanediol, 0.4 part of phenoxyethanol, and a proper amount of purified water.
Example 4
The embodiment provides an anti-wrinkle composition, which comprises, by weight, 10 parts of hexapeptide, 1 part of nicotinamide, 4 parts of glycerol, 2 parts of butanediol, 0.4 part of phenoxyethanol and a proper amount of purified water.
Example 5
This example provides an anti-wrinkle composition, which includes, in parts by weight, 0.3 part of a polypeptide nano-hybrid, 1 part of nicotinamide, 4 parts of glycerol, 2 parts of butylene glycol, 0.4 part of phenoxyethanol, and an appropriate amount of purified water.
Example 6
The embodiment provides an anti-wrinkle composition, which comprises, by weight, 22 parts of a polypeptide nano-hybrid, 1 part of nicotinamide, 4 parts of glycerol, 2 parts of butanediol, 0.4 part of phenoxyethanol, and a proper amount of purified water.
Example 7
This example provides an anti-wrinkle composition, which includes, by weight, 1 part of niacinamide, 4 parts of glycerin, 2 parts of butylene glycol, 0.4 part of phenoxyethanol, and an appropriate amount of purified water.
Example 8
The embodiment provides an anti-wrinkle composition, which comprises, by weight, 10 parts of a polypeptide nano-hybrid, 4 parts of glycerol, 2 parts of butanediol, 0.4 part of phenoxyethanol, and an appropriate amount of purified water.
Example 9
The present embodiment provides a method for preparing an anti-wrinkle composition, the method comprising the steps of:
s1, respectively weighing the following raw materials: glycerin, butanediol, nicotinamide, polypeptide nano-composition, phenoxyethanol and purified water.
S2, sequentially adding the purified water, the glycerol and the butanediol weighed in the step S1 into a container for mixing, heating to 80-85 ℃, and uniformly stirring to obtain a phase A;
s3, cooling to 40-45 ℃, adding the nicotinamide, the polypeptide nano composition and the phenoxyethanol weighed in the step S1 into the phase A obtained in the step S2, and stirring for 20-30min to obtain the anti-wrinkle composition.
Effect verification
And (3) testing a sample: examples 1 to 8 samples prepared according to the preparation method of example 9, respectively.
The experimental method comprises the following steps: the samples prepared in examples 1 to 8 were subjected to an effective substance concentration test, accelerated aging was conducted using the principle of accelerated aging at high temperature, and changes in the effective content with the passage of time were judged to explain the stability of the effective ingredient, and the samples prepared in examples 1 to 8 were placed at room temperature for 3 days and at 50 ℃ for 30 days, respectively, and the concentration of the effective substance was measured using an amino acid analyzer, according to the method described in the second part of pharmacopoeia 2020. The results of the experiments are shown in table 1 below.
The experimental results are as follows:
TABLE 1
As can be seen from table 1, the samples prepared in examples 1, 2 and 3 of the present invention have an effective concentration of 65% or more after being placed at 50 ℃ for 30 days, and the effective concentration of the anti-wrinkle composition of the present invention is optimized to have a formula of 90% or more. And the effective concentration content of the samples prepared in the examples 4 to 6 is reduced to below 0.004mg after the samples are placed at 50 ℃ for 30 days. The sample prepared in example 7 had no polypeptide nanocomposition added, so the test result was 0; the sample prepared in example 8 has no nicotinamide added, and the activity of the polypeptide nano-hybrid is not protected, so the test result is not ideal. The effective concentration content of the sample prepared in example 3 of the present invention was 5.5 times higher than that of the sample prepared in example 4. Namely, the samples prepared in the examples 1, 2 and 3 of the present invention have good stability and are not easily degraded.
Also, to further illustrate the benefits of the present invention, the following examples are provided:
example 4.1 is provided, which differs from example 4 in that: replacing nicotinamide of the invention with D-panthenol;
an anti-wrinkle composition was prepared in combination with the preparation method of the present invention and tested according to the experimental method of experiment 1. The effect of the anti-wrinkle composition prepared in example 4.1 was observed. The results were similar to those in example 4 above.
Also, to further illustrate the benefits of the present invention, the following examples are provided:
example 5.1 is provided, which example 5.1 differs from example 5 in that: adjusting the weight part of the nicotinamide of the invention to 0.05 part;
example 5.2 is provided, which example 5.2 differs from example 5 in that: adjusting the weight part of the glycerol to 0.3 part;
example 5.3 is provided, which example 5.3 differs from example 5 in that: adjusting the weight portion of the butanediol of the invention to 0.3 portion;
the anti-wrinkle composition prepared in combination with the preparation method of the present invention was tested according to the experimental method of experiment 1. The effect of the anti-wrinkle compositions prepared in example 5.1, example 5.2, and example 5.3 was observed. The results were similar to those in example 5 above.
Also, to further illustrate the benefits of the present invention, the following examples are provided:
example 6.1 is provided, which example 6.1 differs from example 6 in that: adjusting the weight part of the nicotinamide of the invention to 1.5 parts;
example 6.2 is provided, which example 6.2 differs from example 6 in that: the weight portion of the glycerol is adjusted to 9 portions;
example 6.3 is provided, which example 6.3 differs from example 6 in that: adjusting the weight part of the butanediol of the invention to 9 parts;
the anti-wrinkle composition prepared in combination with the preparation method of the present invention was tested according to the experimental method of experiment 1. The effect of the anti-wrinkle compositions prepared in example 6.1, example 6.2, and example 6.3 was observed. The results were similar to those in example 6 above.
Experiment 2
And (3) testing a sample: examples 1 to 8 samples prepared according to the preparation method of example 9, respectively.
The experimental method comprises the following steps: the samples prepared in examples 1-8 were subjected to in vitro experiments of drug permeation through the skin (or artificial membrane), the drug was placed in a dosing reservoir, the concentration of the drug in the medium in the receiving reservoir on the other side of the skin was measured at given time intervals, and the rate of drug permeation through the skin was analyzed. The results of the experiment are shown in FIG. 1.
As can be seen from fig. 1, the permeation rates of the samples prepared in examples 1, 2 and 3 of the present invention are all faster, and the permeation rate of example 3 of the present invention is much higher than those of examples 4 to 8, which indicates that the samples prepared in the present invention can permeate into the skin more easily to exert corresponding effects.
Also, to further illustrate the benefits of the present invention, the following examples are provided:
example 4.1 is provided, which differs from example 4 in that: replacing nicotinamide of the invention with D-panthenol;
an anti-wrinkle composition was prepared in combination with the preparation method of the present invention and tested according to the experimental method of experiment 2. The effect of the anti-wrinkle composition prepared in example 4.1 was observed. The results were similar to those in example 4 above.
Also, to further illustrate the benefits of the present invention, the following examples are provided:
example 5.1 is provided, which example 5.1 differs from example 5 in that: adjusting the weight part of the nicotinamide to 0.05 part;
example 5.2 is provided, which example 5.2 differs from example 5 in that: adjusting the weight part of the glycerol to be 0.3 part;
example 5.3 is provided, which example 5.3 differs from example 5 in that: adjusting the weight portion of the butanediol of the invention to 0.3 portion;
the anti-wrinkle composition prepared by combining the preparation method of the invention was tested according to the experimental method of experiment 2. The effect of the anti-wrinkle compositions prepared in example 5.1, example 5.2, and example 5.3 was observed. The results were similar to those in example 5 above.
Likewise, to further illustrate the benefits of the present invention, the following examples are provided:
example 6.1 is provided, which example 6.1 differs from example 6 in that: adjusting the weight part of the nicotinamide of the invention to 1.5 parts;
example 6.2 is provided, which example 6.2 differs from example 6 in that: adjusting the weight part of the glycerol to 9 parts;
example 6.3 is provided, which example 6.3 differs from example 6 in that: adjusting the weight part of the butanediol of the invention to 9 parts;
the anti-wrinkle composition prepared by combining the preparation method of the invention was tested according to the experimental method of experiment 2. The effect of the anti-wrinkle compositions prepared in example 6.1, example 6.2, and example 6.3 was observed. The results were similar to those in example 6 above.
Experiment 3
And (3) testing a sample: examples 1 to 4 samples prepared according to the preparation method of example 9, respectively.
The experimental method comprises the following steps: 120 volunteers, aged between 28-55 years, were summoned in a 30 person group and were subjected to a safety test. Wherein, the index of the anti-wrinkle effect of the pointer is as follows: the texture, elasticity and wrinkles were tested by a German CK instrument and the real-time and long-term efficacy tests were performed, respectively. The specific index judgment basis of the efficacy verification is as follows: instrument values >3 after use than before use are significant.
Immediate efficacy: and (4) carrying out average processing on the immediate efficacy data which are measured before nursing and measured within one hour after nursing, and calculating the improvement degree after nursing, so as to obtain the proportion of the improved people and the proportion of the non-improved people. The results of the experiments are shown in table 2 below.
Long-term efficacy: the original data before nursing and the data of one week to four weeks after the volunteers use are taken as long-term efficacy data to be subjected to average value processing, and the improvement degree of the test sample used by each volunteer is calculated, so that the improved population ratio and the non-improved population ratio are obtained. The results of the experiments are shown in Table 3 below.
Pictures are taken before and 28 days after smearing the paint on volunteers, and the indexes of the anti-wrinkle effect of the pointer are as follows: wrinkles were tested by VISIA instruments and each was validated for 28 days efficacy, giving results of wrinkle removal effect on skin after 28 days. The experimental results of the volunteers of example 1 are shown in fig. 2, the experimental results of the volunteers of example 2 are shown in fig. 3, the experimental results of the volunteers of example 3 are shown in fig. 4, and the experimental results of the volunteers of example 4 are shown in fig. 5. As can be seen from fig. 2 to 5, the skin wrinkle-removing effect of fig. 4 is most remarkable, and wrinkles are not substantially seen after 28 days; fig. 2 and 3 also have a good skin wrinkle-removing effect, whereas the skin wrinkle-removing effect of fig. 5 is weak.
The skin thickness and density tests were performed on volunteers before and after 7, 14, 21, 28 days of use, and are indicative of an indication of anti-wrinkle effect: skin thickness and skin density were tested by danish instrument for efficacy verification before use and for 7, 14, 21, 28 days respectively, to give results on skin wrinkle removal effect after 28 days. The results of the experiment are shown in Table 4 below.
TABLE 2
TABLE 3
TABLE 4
As can be seen from tables 2 and 3, the samples prepared in examples 1, 2 and 3 of the present invention were subjected to the immediate test and the four-week long-term test, and it was found that the texture, skin elasticity and skin wrinkles of the volunteers using examples 1 to 3 of the present invention all had immediate and long-term anti-wrinkle effects, and the immediate and long-term anti-wrinkle effects of the volunteers using example 3 of the present invention were more significant. The volunteers of example 4 who did not use the formulation of the present invention had poor immediate and long-term anti-wrinkle effects.
As can be seen from table 4, the skin thickness increase rate is example 3 > example 2 > example 1 > example 4, and the skin density increase rate is example 3 > example 2 > example 1 > example 4, i.e. examples 1 to 3 of the present invention have significant effects on the increase of the skin thickness and the skin density, and example 3 of the present invention has more significant effects on the increase of the skin thickness and the skin density, and the increase of the skin density and the skin thickness has a good characterization on the anti-wrinkle effect, so the anti-wrinkle composition of the present invention has a good anti-wrinkle effect. Example 4 has no significant effect on the increase in skin thickness and skin density compared to example 1, example 2 and example 3.
As can be seen from fig. 2 to 5, VISIA photographs of the volunteers using examples 1 to 3 of the present invention showed that skin wrinkles were lightened and lightened, and the volunteers using example 3 of the present invention showed significantly less wrinkles. While the change in wrinkles was not apparent in the volunteers of example 4 who did not use the formulation system of the present invention.
It is to be understood that the invention disclosed is not limited to the particular methodology, protocols, and materials described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (10)
1. An anti-wrinkle composition, characterized in that the composition comprises a polypeptide nanohybrid, niacinamide, a humectant, a preservative and water.
2. The composition according to claim 1, wherein the structure of the polypeptide nano-hybrid is [ Au-S-pentadecapeptide ] n, preferably the amino acid sequence of the pentadecapeptide is sefmrneeleemqrra.
3. The composition of claim 1, wherein the preservative is one or more of methylparaben, propylparaben, phenoxyethanol, glyceryl caprylate, ethylhexyl glycerin, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, caprylhydroxamic acid, and glyceryl caprylate.
4. The composition of claim 1, wherein the humectant is one or more of glycerin, diglycerin, propylene glycol, butylene glycol, methyl gluceth-10, methyl gluceth-20, glyceryl polyether-7, glyceryl polyether-26, glyceryl glucoside, sucrose, rhamnose, mannose, raffinose, betaine, erythritol, and xylitol.
5. The composition of claim 3 or 4, wherein the preservative is phenoxyethanol; the humectant is glycerin, butylene glycol or a mixture thereof.
6. The composition of claim 1, wherein the composition comprises, by weight, 0.5 to 20 parts of the polypeptide nano-hybrid, 0.1 to 1 part of nicotinamide, 1 to 8 parts of the humectant, 0 to 0.4 part of the preservative, and water.
7. The composition of claim 6, wherein the composition comprises, in parts by weight, 10 parts of the polypeptide nano-hybrid, 1 part of nicotinamide, 6 parts of the humectant, 0.4 part of the preservative, and water.
8. The composition of claim 7, wherein the composition comprises, in parts by weight, 10 parts of the polypeptide nano-hybrid, 1 part of nicotinamide, 4 parts of glycerol, 2 parts of butanediol, 0.4 part of phenoxyethanol, and water.
9. A method of making an anti-wrinkle composition according to any one of claims 1-8, the method comprising the steps of:
s1, respectively weighing the following raw materials: humectant, nicotinamide, polypeptide nano-composition, preservative and purified water.
S2, adding the purified water and the humectant weighed in the step S1 into a container, mixing, heating to 80-85 ℃, and uniformly stirring to obtain a phase A;
s3, cooling to 40-45 ℃, adding the nicotinamide, the polypeptide nano composition and the preservative which are weighed in the step S1 into the phase A obtained in the step S2, and stirring for 20-30min to obtain the anti-wrinkle composition.
10. Use of an anti-wrinkle composition according to any one of claims 1-8 in the manufacture of an anti-wrinkle product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210865461.XA CN115337223A (en) | 2022-07-21 | 2022-07-21 | Anti-wrinkle composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210865461.XA CN115337223A (en) | 2022-07-21 | 2022-07-21 | Anti-wrinkle composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115337223A true CN115337223A (en) | 2022-11-15 |
Family
ID=83949840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210865461.XA Pending CN115337223A (en) | 2022-07-21 | 2022-07-21 | Anti-wrinkle composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115337223A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110033507A1 (en) * | 2006-02-16 | 2011-02-10 | Sederma | Polypeptides KXK and Their Use |
| CN102440943A (en) * | 2011-08-25 | 2012-05-09 | 唯美度科技（北京）有限公司 | Composition for caring and improving aged or damaged skin |
| CN106963661A (en) * | 2017-04-10 | 2017-07-21 | 深圳科婷科技有限公司 | Argireline compacts elite stoste and preparation method thereof |
| CN113402586A (en) * | 2021-06-28 | 2021-09-17 | 陕西未来多肽生物科技有限公司 | Polypeptide and application thereof |
| CN113512092A (en) * | 2021-06-28 | 2021-10-19 | 陕西未来多肽生物科技有限公司 | Polypeptide nano hybrid and application thereof |
| CN114010518A (en) * | 2021-10-22 | 2022-02-08 | 广东润和生物科技有限公司 | Coenzyme Q10 essence lotion for moisturizing, whitening and promoting repair and preparation method thereof |
-
2022
- 2022-07-21 CN CN202210865461.XA patent/CN115337223A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110033507A1 (en) * | 2006-02-16 | 2011-02-10 | Sederma | Polypeptides KXK and Their Use |
| CN102440943A (en) * | 2011-08-25 | 2012-05-09 | 唯美度科技（北京）有限公司 | Composition for caring and improving aged or damaged skin |
| CN106963661A (en) * | 2017-04-10 | 2017-07-21 | 深圳科婷科技有限公司 | Argireline compacts elite stoste and preparation method thereof |
| CN113402586A (en) * | 2021-06-28 | 2021-09-17 | 陕西未来多肽生物科技有限公司 | Polypeptide and application thereof |
| CN113512092A (en) * | 2021-06-28 | 2021-10-19 | 陕西未来多肽生物科技有限公司 | Polypeptide nano hybrid and application thereof |
| CN114010518A (en) * | 2021-10-22 | 2022-02-08 | 广东润和生物科技有限公司 | Coenzyme Q10 essence lotion for moisturizing, whitening and promoting repair and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3468983B1 (en) | Peptide, composition comprising said peptide and uses thereof, in particular cosmetic uses | |
| AU2012234366B2 (en) | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
| CN106038351B (en) | It is a kind of for desalinating the peptide composition of wrinkle | |
| JP5596922B2 (en) | Cosmetic or dermatological pharmaceutical composition comprising an enkephalin-derived peptide for reducing and / or removing facial wrinkles | |
| KR101757946B1 (en) | Compounds which inhibit muscle contraction | |
| KR20190085136A (en) | Compounds useful for the treatment and / or care of skin, hair, nails and / or mucosa | |
| JP2018500330A (en) | Peptide compounds, compositions containing them and uses of said compounds, in particular cosmetic applications | |
| WO2019008452A1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| WO2020161683A1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| WO2020031146A1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| JP4950571B2 (en) | Composition having ability to promote collagen production | |
| EP3773460B1 (en) | Use of a peptide for the treatment of epiderm | |
| CN115337223A (en) | Anti-wrinkle composition and application thereof | |
| JPH0543442A (en) | Skin cosmetic | |
| CN113749967B (en) | Peptide composition and application thereof | |
| KR101865841B1 (en) | Cosmetic composition for improving skin wrinkle using nano capsule method with excellent skin permeability and stability | |
| CN113549139A (en) | Conus polypeptide, polypeptide composition, preparation method and application thereof | |
| KR101224809B1 (en) | Retinoic acid derivative, process for preparing the same, and cosmetic composition comprising the same | |
| CN109152757A (en) | N- lipoic acid-amino acid or peptide, derivative and their purposes | |
| JPH0253799A (en) | Novel peptide and antimicrobial agent | |
| CN111087451B (en) | Compound capable of increasing skin wrinkle resistance function and application thereof in preparation of cosmetics | |
| JP6132299B2 (en) | Composition comprising collagen | |
| TW202329993A (en) | Method for producing extract, method for producing cosmetic, and method for producing substance for oral use | |
| CN111773155A (en) | Stable peptide containing active matter from fermentation source | |
| JPH03123716A (en) | Melanocyte-stimulating hormone antagonist and skin external preparation containing the same antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221115 |